Events Calendar

REGISTER HERE

Type 1 Diabetes (T1D) is a complex, lifelong autoimmune condition that can affect anyone, regardless of age, lifestyle, or family history. It is often diagnosed late in its progression (stage 3), when symptoms appear, increasing the risk of complications and hospitalization. However, screening for autoantibodies can now detect T1D months or even years before the first symptoms appear.

Despite this, screening is not yet part of standard of care, due to unclear guidelines and inconsistencies in treatment pathways. With advancements in disease-modifying therapies (DMTs) that can impact the course of early-stage disease, there is a need to optimize and scale current screening practices. Global momentum for T1D early detection is growing, supported by new clinical guidelines and legislative initiatives, such as Italy’s groundbreaking screening law and EDENT1FI, a Horizon Europe project aiming to integrate screening within healthcare systems across Europe.

The Early Detection Policy Forum, co-organized by Breakthrough T1D NL (formerly JDRF), Diabetes+, Diabeter, the Dutch Diabetes Association, and Sanofi, in media partnership with Euractiv, is part of a broader effort to translate these advancements into actionable policy strategies at both local and European levels. As recently highlighted by Commissioner Várhelyi during his meeting with the European Diabetes Forum (EUDF), Europe has a unique opportunity to drive transformative change in diabetes care.

Held alongside the 18th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), in Amsterdam, this hybrid side event will bring together healthcare experts, advocates, and policymakers to address these key questions:

· What are the benefits of T1D early detection in relatives?
· How can we transition from screening to monitoring and turn insights into action?
· What policy advancements are needed to scale T1D early detection across Europe?

Join the conversation to help shape the future of early detection and drive policy advancements in T1D care across Europe.